Gentronix has revealed a new corporate identity and re-designed website. The new identity has been developed to reflect how the company has evolved into a mainstream provider of early screening in vitro genetic toxicology assays, and mechanistic follow-up, to a range of business sectors including pharmaceuticals, chemicals, agrochemicals, flavours fragrances and taste enhancers, and the personal care and consumer product industries.
In addition to classical in vitro early screening assays, such as the Ames bacterial mutation reversal and Micronucleus tests, Gentronix offers their proprietary GreenScreen® HC and BlueScreen™ HC assays.
The company also supports clients in the development of de-risking strategies and carrying out further assays to determine the mechanism and causes of positive genotox screening results.
As such, Gentronix has a wealth of knowledge and experience in the field and this is reflected in the new website at www.gentronix.co.uk which hosts content on the science of genotoxicity, regulations for each industry sector, screening procedures, as well as links to an extensive range of peer reviewed papers.
John Nicholson, CEO at Gentronix, comments, “In recent years we have greatly diversified our range of genotoxicity screening product and service offerings. We also provide advice on dealing with positive results and are able to offer a variety of further assays and strategies to help understand the mechanism of genotoxicity. This updating of our corporate identity has been undertaken to better reflect this. These are exciting times for Gentronix, and we feel that the new identity and website helps us to build on our strong foundations to move the business forward.”